Novo Nordisk has finally launched popular weight loss drug Wegovy in China, five months after its approval by authorities there. The drug will sell for 1,400 yuan ($193.27), compared to the U.S. list price of $1,349 for a months supply.
As Chinese oncology drugs gain clout, expect these drugs to continue to penetrate the global market in the next few years. One notable milestone was U.S. approval of toripalimab as a first-line treatment for adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC) in October 2023. Even with a significant markup — a single-dose vial costs $280 in China — it was a lot cheaper than the wholesale price in the U.S. ($8,892).
这两天UnitedHealthcare CEO被击毙,网上议论不少,因为UHC牟取了暴利。
那么药公司是怎么赚病人钱的呢?
例子一
Wegovy 是一种美国生产的减肥药,被批准在中国卖,价格为1400元($193)一个月, 而在美国则要$1349一个月。 差不多1:7。
https://www.biospace.com/drug-delivery/novos-wegovy-launched-in-china-at-a-fraction-of-us-price
Novo Nordisk has finally launched popular weight loss drug Wegovy in China, five months after its approval by authorities there. The drug will sell for 1,400 yuan ($193.27), compared to the U.S. list price of $1,349 for a months supply.
例子二
Toripalimab是一种中国上海君实生物公司生产的抗癌药,在中国一针是$280。 美国FDA也批准使用,但是一针是$8892。 价格差不多1:31。
https://www.outsourcedpharma.com/doc/china-s-rising-role-on-the-global-stage-in-the-oncology-market-0001
As Chinese oncology drugs gain clout, expect these drugs to continue to penetrate the global market in the next few years. One notable milestone was U.S. approval of toripalimab as a first-line treatment for adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC) in October 2023. Even with a significant markup — a single-dose vial costs $280 in China — it was a lot cheaper than the wholesale price in the U.S. ($8,892).
美国药公司赚钱跟UHC也差不多吧?
有FDA把关这个是不错,但药公司为了过FDA这关,除了有正常的R&D人员,还要雇一堆搞paperwork的人。 往往一个产品,上报的文件数千页。 老实说,绝大多数都是浮于形式,哪个审核人员能读完那几千页的document?
相信以前中国的"投机倒把"都不敢这么加价吧
中国开发新药成本比美国低多了,现在很多临床实验在中国做。美国做不起,连病人都enroll 不到。Toripalimab是个PD_1 抗体。国内做PD1的一堆。
只是,以后美国就会丢失海外的份额
类似还有,电动车,星舰,AI。最难的都是第一步。你看中国都是在仿制美国,就是让美国人但了最大风险。当然在中国做仿制品也比在美国便宜。